公开(公告)号：US09056913B2

公开(公告)日：2015-06-16

申请号：US13895574

申请日：2013-05-16

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA ,  INFECTIOUS DISEASE RESEARCH INSTITUTE

Inventor： Rhea Coler ,  Yves Lobet ,  Steven Reed

IPC: A61K39/04 ,  A61K49/00 ,  A61K39/02 ,  C07K14/35 ,  A61K31/4409 ,  A61K31/496 ,  A61K39/00

CPC classification number: A61K39/04 ,  A61K31/4409 ,  A61K31/496 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/575 ,  C07K14/35

Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Abstract translation: 本发明涉及通过施用包含编码Mtb72f融合蛋白或Mtb72f融合蛋白或其免疫原性片段的核酸的药物组合物，例如与佐剂一起施用来防止活性和潜伏性结核分枝杆菌感染的再活化的方法 。 Mtb72f核酸或融合蛋白可以与一种或多种对结核分枝杆菌感染有效的化学治疗剂一起施用。 所述方法还提供了缩短化疗方案针对结核分枝杆菌感染的时间过程。

公开(公告)号：US20140050776A1

公开(公告)日：2014-02-20

申请号：US13895574

申请日：2013-05-16

Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE ,  GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Rhea COLLER ,  Yves Lobet ,  Steven Reed

IPC: C07K14/35 ,  A61K31/4409 ,  A61K31/496 ,  A61K39/04

CPC classification number: A61K39/04 ,  A61K31/4409 ,  A61K31/496 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/575 ,  C07K14/35

Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Abstract translation: 本发明涉及通过施用包含编码Mtb72f融合蛋白或Mtb72f融合蛋白或其免疫原性片段的核酸的药物组合物，例如与佐剂一起施用来防止活性和潜伏性结核分枝杆菌感染的再活化的方法 。 Mtb72f核酸或融合蛋白可以与一种或多种对结核分枝杆菌感染有效的化学治疗剂一起施用。 所述方法还提供了缩短化疗方案针对结核分枝杆菌感染的时间过程。

公开(公告)号：US20250099576A1

公开(公告)日：2025-03-27

申请号：US18964896

申请日：2024-12-02

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Giulietta MARUGGI ,  Kambiz MOUSAVI ,  Newton WAHOME ,  Jason William WESTERBECK ,  Magdalena Aleksandra ZWIERZYNA ,  Yoo-Ah KIM ,  Amirali YAZDI ,  Yamina BENNASSER

IPC: A61K39/215 ,  A61K9/51 ,  A61K39/00 ,  C07K14/005 ,  C07K16/10 ,  C12P19/34

Abstract: Provided herein are 3′ and 5′ UTRs that provide an amount, duration, or both of protein expression from a recombinant RNA. Compositions of matter, methods, or uses of said 3′ and 5′ UTRs are provided. Provided herein are RNA segments that encode a SARS-CoV-2 omicron spike protein, which provide for omicron-strain-specific immunogenic compositions. Compositions of matter, methods, or uses of said RNA segments that encode a SARS-CoV-2 omicron spike protein are provided.

公开(公告)号：US20250064912A1

公开(公告)日：2025-02-27

申请号：US18824050

申请日：2024-09-04

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Mariagrazia PIZZA ,  Steven B. BLACK

IPC: A61K39/095 ,  A61K39/00 ,  A61K39/116 ,  A61K39/39 ,  A61K47/64 ,  C07K14/22 ,  C07K16/12

Abstract: A method for immunizing a subject in need thereof against Neisseria gonorrhoeaeby administering an immunogenic composition comprising meningococcal outer membrane vesicles (OMVs).

公开(公告)号：US12227540B2

公开(公告)日：2025-02-18

申请号：US18098949

申请日：2023-01-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Ahmad Taimour Baig ,  Felicie Georgette Colette Denet ,  Juan Jose Diaz Garcia ,  Chad Austin Farrenburg ,  Lora Lea Lawrence ,  Kent Raymond Myers ,  Jeri Kay Sandvick ,  Jeb Yeatts Vandenburg

IPC: A61K39/39 ,  A61K39/00 ,  A61K39/12 ,  A61K39/25 ,  C07J63/00 ,  C12N7/00

Abstract: Saponin extracts containing at least 93% QS-21 main peak and 0.25-3% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects.

公开(公告)号：US12161707B2

公开(公告)日：2024-12-10

申请号：US15693663

申请日：2017-09-01

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Mariagrazia Pizza ,  Marzia Monica Giuliani ,  Elisabetta Monaci

IPC: A61K39/095 ,  A61K39/116 ,  A61K39/39 ,  A61K47/64 ,  C07K14/22 ,  C07K16/12 ,  A61K39/00

Abstract: Methods and compositions for immunizing a human subject against Neisseria gonorrhoeae.

公开(公告)号：US20240327470A1

公开(公告)日：2024-10-03

申请号：US18438870

申请日：2024-02-12

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Matthew BOTTOMLEY ,  Vega MASIGNANI

IPC: C07K14/22 ,  A61K39/00 ,  A61K39/095

CPC classification number: C07K14/22 ,  A61K39/095 ,  A61K2039/575 ,  C07K2319/33

Abstract: The inventors have identified residues within variant 2 and variant 3 of meningococcal fHpb which can be modified to enhance their properties.

公开(公告)号：US20240293535A1

公开(公告)日：2024-09-05

申请号：US18262033

申请日：2022-01-18

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Johann MOLS ,  Marie TOUSSAINT

IPC: A61K39/245 ,  A61P31/22 ,  C07K14/005

CPC classification number: A61K39/245 ,  A61P31/22 ,  C07K14/005 ,  C12N2710/16622 ,  C12N2710/16634

Abstract: The present invention relates to a HSV2 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV1 in a subject. Also provided is a HSV1 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV2 when administered to a subject.

公开(公告)号：US20240285755A1

公开(公告)日：2024-08-29

申请号：US18562520

申请日：2022-05-20

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Emmanuel Jules HANON

IPC: A61K39/39 ,  A61K39/00

CPC classification number: A61K39/39 ,  A61K2039/53 ,  A61K2039/55561

Abstract: The present invention relates to immunisation using carrier-formulated mRNA in conjunction with an adjuvant comprising a STING agonist, and to related aspects.

公开(公告)号：US20240277824A1

公开(公告)日：2024-08-22

申请号：US18402174

申请日：2024-01-02

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Fabiana FERNANDEZ ,  Michael KOWARIK ,  Michael WACKER ,  Michael WETTER

IPC: A61K39/112 ,  A61K39/00 ,  A61K39/02 ,  A61K39/104 ,  A61K39/108 ,  A61K39/385 ,  C07K14/195

CPC classification number: A61K39/0283 ,  A61K39/0258 ,  A61K39/104 ,  A61K39/105 ,  A61K39/385 ,  C07K14/195 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/6087 ,  C07K2319/034 ,  Y02A50/30

Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.